Stratos Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$223K Sell
6,058
-190
-3% -$9K 0.01% 560
2025
Q4
$318K Buy
6,248
+1,648
+36% +$84.3K 0.02% 517
2025
Q3
$255K Buy
4,600
+672
+17% +$39.3K 0.01% 593
2025
Q2
$271K Buy
3,928
+832
+27% +$56.6K 0.01% 566
2025
Q1
$215K Sell
3,096
-2,755
-47% -$228K 0.01% 615
2024
Q4
$503K Sell
5,851
-4,216
-42% -$456K 0.02% 473
2024
Q3
$1.2M Sell
10,067
-1,115
-10% -$149K 0.06% 321
2024
Q2
$1.6M Sell
11,182
-581
-5% -$77K 0.08% 245
2024
Q1
$1.51M Buy
11,763
+5,777
+97% +$688K 0.09% 241
2023
Q4
$619K Buy
5,986
+3,383
+130% +$335K 0.04% 423
2023
Q3
$237K Buy
+2,603
New +$229K 0.02% 585
2022
Q3
Sell
-3,582
Closed -$200K 522
2022
Q2
$200K Buy
+3,582
New +$199K 0.02% 496

Other funds holding NVO

Stratos Wealth Advisors's NVO Position: Q1 2026 in Review

Stratos Wealth Advisors reduced its Novo Nordisk (NVO) stake by 3% in Q1 2026, selling an estimated $9K and leaving 6,058 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #560.

Stratos Wealth Advisors first reported a position in NVO in Q2 2022 and has held it in 12 quarters since. The position peaked at $1.6M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Stratos Wealth Advisors held 6,058 shares of Novo Nordisk worth $223K as of Q1 2026.
  • Stratos Wealth Advisors sold 190 Novo Nordisk shares in Q1 2026, an estimated $9K.
  • Novo Nordisk made up 0.01% of Stratos Wealth Advisors's portfolio in Q1 2026, its #560 holding.
  • Stratos Wealth Advisors first reported a position in Novo Nordisk in Q2 2022 and has held it in 12 quarters since.
  • Stratos Wealth Advisors's Novo Nordisk position peaked at $1.6M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.